INTRODUCTION
Worldwide, clinical manifestations of cardiovascular diseases, such as acute coronary syndrome (ACS), coronary artery disease (CAD), and ischemic stroke, are among the leading causes of death [1] . The underlying pathogenetic mechanisms of ACS are multifactorial but finally lead via platelet activation to intravascular clot formation and vessel occlusion with ischemia of the downstream located tissue [2] .
Platelet activation, which commonly occurs when platelets are exposed to subendothelial structures such as fibrinogen, is a physiological process of primary hemostasis. Activation of the glycoprotein (GP)Ib/V/IX, which is expressed on the surface of platelets, mediates the initial tethering of platelets to the vessel wall. Binding of the platelets to von Willebrand factor, which is exposed in subendothelial tissues following vascular injury, triggers an interaction between GPVI and collagen. Autocrine and paracrine stimulation of platelet receptors by potent platelet-aggregating agonists and vasoconstrictors, such as thromboxane A2 (TXA2), platelet-activating factor, and adenosine diphosphate (ADP), lead to activation of an integrin called GPIIb/IIIa, which is also expressed on the platelet surface.
As a result, the soluble plasma coagulation factor, fibrinogen, binds to this receptor and mediates platelet-to-platelet aggregation, and consequently, a primary platelet plug, or thrombus, at the site of injury is formed. Another important platelet agonist is thrombin. It is generated in the coagulation cascade, a pathway of secondary hemostasis, which is activated simultaneously with primary hemostasis. A main function of thrombin is the conversion of fibrinogen to the insoluble protein fibrin, the major stabilizing component of the thrombus. Physiologic activation of these pathways contributes to the prevention and control of bleeding events.
Notably, pathological platelet activation causes thrombus formation in conditions other than after vascular injury, such as after plaque rupture [3] . The stationary or traveling thrombus (embolism) may cause the occlusion of arteries and subsequent ischemic cell death [3] resulting in ACS or a myocardial infarction (MI). Invasive treatment options in ACS include coronary revascularization with percutaneous coronary intervention (PCI) or in rare cases acute coronary artery bypass graft surgery.
CURRENT ANTIPLATELET THERAPY
Enhanced platelet activation can be found in ACS patients and often leads to thrombus formation and cardiac ischemia. Hence, international cardiac societies recommend the use of antiplatelet drugs, e.g., acetylsalicylic acid (ASA) and P2Y12 antagonists for these patients in order to reduce ischemic complications [4] [5] [6] .
ASA is an irreversible cyclooxygenase-1 inhibitor, and thereby reduces intraplatelet production of prothrombotic TXA2 with consecutive inhibited platelet aggregation.
P2Y12 antagonists (clopidogrel, prasugrel, and ticagrelor) avoid ADP-mediated platelet activation and aggregation.
The benefit of ASA and P2Y12 antagonists in ACS patients has been shown in several large clinical studies [7] . However, the risk of further thrombotic events remains high [8] . respectively [9] . The underlying phenomenon for this observation might be related to alternative platelet activation pathways, such as those mediated by thrombin [8] .
Clinical trials have demonstrated that even a double antiplatelet therapy with ASA and clopidogrel is insufficient in about one-third of all treated patients resulting in recurrent atherothrombotic events [10, 11] . Several clinical trials were designed to compare treatment regimens of clopidogrel to prasugrel and ticagrelor, which are known to more effectively inhibit P2Y12 mediated platelet aggregation [12, 13] . In the trial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel (TRITON-TIMI 38), prasugrel had superior efficacy compared with clopidogrel [12] . The composite endpoint of death from cardiovascular causes, nonfatal MI, or nonfatal stroke was 9.9% for prasugrel compared with 12.1% for clopidogrel. However, the rate of thrombolysis in MI (TIMI) major bleeding was elevated in patients receiving prasugrel compared with patients receiving clopidogrel (2.4% vs. 1.8%, respectively) [12] . In the PLATelet inhibition and patient Outcomes trial (PLATO), ticagrelor also demonstrated superior efficacy compared with clopidogrel as only 9.0% of patients experienced the primary endpoint of cardiovascular death, MI, or stroke compared with 10.7% of patients taking clopidogrel [13] . Yet, similar to prasugrel, an increase in the rate of bleeding was observed with ticagrelor compared with clopidogrel [13] . 
PROTEASE-ACTIVATED RECEPTOR INHIBITORS
Targeting alternative pathways, which are not affected by ASA or P2Y12 antagonists, is one potential way to improve the treatment options. Protease-activated receptors (PAR-1, PAR-2, PAR-3, and PAR-4) are G-proteincoupled receptors expressed on platelets and other cells that are not involved in platelet activation (e.g., neurons, myocytes, fibroblasts, and endothelial cells) [8, 14] . Thrombin has the highest affinity for PAR-1, but also activates PAR-3 and PAR-4, whereas PAR-2 is activated by trypsin and other proteases, but not by thrombin. Only PAR-1 and PAR-4 are expressed on platelets.
The principle thrombin receptor, PAR-1, mediates platelet activation at subnanomolar concentrations, whereas the other thrombin receptor, PAR-4, requires higher thrombin concentrations for activation [14] . This review provides an overview of the two PAR-1 antagonists in the most advanced stages of development: vorapaxar [SCH530349; Merck & Co., Whitehouse Station, NJ, USA (following its merger with Schering-Plough)] and atopaxar (E5555; Eisai, Tokyo, Japan).
Atopaxar (E5555)
Atopaxar is a low molecular weight (608 g/mol) reversible PAR-1 antagonist. It is metabolized by hepatic cytochrome CYP3A4 and eliminated through the gastrointestinal tract [24] . In preclinical studies, atopaxar demonstrated inhibition of thrombin receptor-activating peptides (TRAP)-and thrombin-induced platelet aggregation [25, 26] . Furthermore, atopaxar inhibited multiple other platelet activity biomarkers in plasma samples from healthy volunteers and patients with CAD [27] . A study evaluated the inhibitory effect of atopaxar on TRAP-induced platelet aggregation from healthy volunteers (ASA naive) and patients (n = 10 per group) with CAD who had been treated with ASA (81 mg/day) alone or combined with clopidogrel (75 mg/day) [27] . In plasma samples from healthy volunteers and patients, all concentrations of atopaxar significantly, and almost completely, inhibited TRAP-induced platelet aggregation compared with a vehicle control.
Phase I Studies
The pharmacodynamics and safety properties of atopaxar were evaluated in two studies. In a randomized, double-blind, placebo-controlled, dose-ascending study, 40 healthy volunteers were randomized to receive 20, 50, 100, 200, or 400 mg atopaxar [28] . The 24 volunteers were randomized to three groups receiving 50, 100, or 200 mg atopaxar or placebo for 10 days. It was found that thrombin-induced platelet aggregation was inhibited in a dose-dependent manner, achieving the maximum effect 6 h after onset. Repeated administration inhibited thrombin-induced platelet aggregation almost completely, even 24 h after the last administration. At 7 days after the last medication, platelet function had returned to normal. Coagulation and bleeding times were not influenced demonstrating the specific effect of atopaxar [28] .
At the time of publication, atopaxar had undergone phase II evaluation in a series of clinical trials cumulatively entitled Lesson from Antagonizing the Cellular Effect of Thrombin (LANCELOT) Trial that were undertaken in populations of patients with CAD and ACS in Japanese centers (NCT00540670 and NCT00619164) as well as in centers outside of Japan (NCT00312052 and NCT00548587) [29] [30] [31] .
Phase II Studies
To assess the safety of atopaxar, the Japanese
Lessons from Antagonizing the Cellular Effect of Thrombin (J-LANCELOT) Trial [29] consisting of two multicenter, randomized, double-blind, placebo-controlled phase II studies in Japanese patients with ACS or highrisk artery disease was conducted. In this trial 241 patients with NSTEMI or UA were randomized to 50, 100, or 200 mg atopaxar for 12 weeks including a 400 mg loading dose compared to placebo and placebo loading dose [29] .
In the CAD study, 263 patients were randomized to receive the same doses of atopaxar as in the ACS study. In contrast, they did not receive a loading dose and were treated for 24 weeks [29] . The primary safety endpoint was the incidence of bleeding events adjudicated according to the Clopidogrel in Unstable Angina to Prevent Recurrent Events CURE [32] and TIMI [33] definitions. The secondary endpoint was the incidence of major cardiovascular adverse events (MACE), defined as cardiovascular death, MI, stroke, or recurrent ischemia. Compared to placebo TIMI minor bleeding was not increased in atopaxar treated patients [ACS: 6.6% placebo vs. 5.0% atopaxar (all dose groups); CAD: 1.5% placebo vs. 1.5% atopaxar (all dose groups)] without the occurrence of any TIMI major bleeding [29] . A numerical increase in any TIMI bleeding with the dose of 200 mg atopaxar was observed (ACS:
16.4% placebo vs. 23.0% atopaxar, P = 0.398; CAD: 4.5% placebo vs. 13.2% atopaxar, P = 0.081) [29] . The rate of MACE in the combined atopaxar groups was not different from placebo [ACS: 6.6% placebo vs. The combined results of the phase II clinical trials would have been sufficiently positive to start phase III trials. However, the numerically greater incidence in safety endpoints and AE, such as QTc prolongation and liver enzyme elevation, as well as the lack of a convincing dose-related trend for safety and efficacy of atopaxar, limit the encouraging results of these clinical trials. Currently, the development of atopaxar by Eisai is discontinued.
Vorapaxar (SCH530349)
Vorapaxar is an oral, low-molecular weight (492.58 g/mol), high-affinity, competitive PAR-1 antagonist, which has been shown in preclinical studies to inhibit thrombin and TRAP platelet aggregation without increased bleeding complications [34, 35] . In a phase II trial, vorapaxar administered in addition to standard ASA and clopidogrel to ACS patients was not associated with increased bleeding risks and was well tolerated [36] . The rate of AEs was comparable to the rate of AEs with standard therapy alone. Based on these results, two large, randomized, phase III trials [Thrombin Receptor
Antagonist for Clinical Event Reduction in ACS (TRA-CER) and Thrombin Receptor Antagonist in Secondary Prevention of atherothrombotic ischemic events (TRA-2P)] were initiated to evaluate the safety and efficacy of vorapaxar in combination with the standard-of-care therapy in patients who had NSTE-ACS or established atherosclerosis, respectively [37, 38] . An overview of the results is given in Table 1 . TRA-CER trial was terminated. In addition, the DSMB recommended the termination of the study drug in patients with a history of stroke in the TRA-2P trial.
TRA-CER
The key secondary endpoint (a composite of death from cardiovascular causes, MI, or stroke) occurred in 822 patients in the vorapaxar group and 910 patients in the placebo group (14.7% vs. 16.4%, respectively; HR 0.89, 95% CI 0.81-0.98; P = 0.02) [37] . The reduction in the rate of MI was the main effect observed in the vorapaxar group, compared with the placebo group (11.1% vs. 12.5%; HR 0.88, 95% CI 0.79-0.98; P = 0.02) [37] . However, the rates of death from any cause did not vary significantly (6.5% vs. 6.1%; HR 1.05, 95% CI 0.90-1.23;
The authors conclude that in patients with ACS, the addition of vorapaxar to standard therapy did not significantly reduce the primary composite endpoint but significantly increased the risk of major bleeding, including ICH [37] .
TRA 2P-TIMI50
The TRA 2P-TIMI50 trial evaluated the effect of vorapaxar on patients with a history of atherosclerosis, defined as a spontaneous MI or ischemic stroke within the previous 2 weeks to 12 months or peripheral arterial disease associated with a history of intermittent claudication in conjunction with either an ankle brachial index of less than 0.85 or previous revascularization for limb ischemia [38, 41] . In this study 13,225 patients were randomly assigned to receive vorapaxar (2.5 mg daily) and 13,224 patients to receive placebo.
The median follow-up time was 30 months. As mentioned earlier, the DSMB recommended discontinuing the study treatment in patients with a history of stroke due to an increased risk Taking these data together, looking at the total patient populations vorapaxar reduces the rate of cardiovascular death, MI, or stroke in patients with a history of atherothrombosis who were receiving standard therapy at the cost of increased bleeding, including ICH [38] . To identify patients in which the benefit-risk ratio can be optimized prespecified subanalysis were performed. In the subgroup of patients with a qualifying MI within the previous 2 weeks to 12 months (8,898 patients receiving vorapaxar and 8,881 receiving placebo) the primary endpoint occurred less frequently in vorapaxar-treated patients than in placebotreated patients (8.1% vs. 9.7% in the placebo group; HR 0.80, 95% CI 0.72-0.89; P \ 0.0001) [42] . Conversely, GUSTO moderate or severe bleeding occurred more frequently in the vorapaxar group than in the placebo group (3.4% vs. 2.1%, respectively; HR 1.61, 95% CI 1.31-1.97; P \ 0.0001). Moreover, a numerical increase in ICH in the vorapaxar group compared to the placebo group was observed (0.6% vs. 0.4%, respectively; P = 0.076) [42] .
In another subanalysis including the 3,787 patients with peripheral arterial disease, hospitalizations for acute limb ischemia (2.3% vs. 3.9%; HR 0.58; 95% CI 0.39-0.86; P = 0.006) and peripheral arterial revascularization (18.4% vs. 22.2%; HR 0.84; 95% CI 0.73-0.97; P = 0.017) were lower in the vorapaxar group.
Nonetheless, moderate or severe bleeding was increased with vorapaxar (7.4% vs. 4.5%; HR 1.62; 95% CI 1.21-2.18; P = 0.001) including ICH (0.9% vs. 0.4%; HR 2.03; 95% CI 0.82-5.02; P = 0.13) [43] .
Taken together, vorapaxar in addition to standard treatment may be beneficial in the secondary prevention of patients with established atherosclerosis who have a history of MI [44] . For patients with peripheral arterial disease, vorapaxar might be an option to reduce limb ischemia at the risk of increased bleeding.
New Experimental Par-1 Inhibitors
There are several new experimental PAR-1 inhibitors with different pharmacodynamic profiles and slightly different mechanisms of action, which are currently in preclinical trials [45] . To date, PZ-128 is the furthest along in preclinical trials [46] . In a recently published meta-analysis on PAR-1 antagonists, Chatterjee et al. [47] found that PAR-1 antagonists in addition to standard medical therapy may reduce the risk of cardiovascular mortality and recurrent MI but also enhances bleeding.
CURRENT OPINION
Until now no clinical approval has been granted for PAR-1 antagonists. The future of this novel class of antithrombotic drugs will depend on the identification of patient groups in which the risk-benefit ratio is favorable. Moreover, it is not known how PAR-1 blockers interfere with the new P2Y12 antagonists, prasugrel and ticagrelor.
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